NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

"Understanding the NICE economic evaluation process."

Longfellow95,

Thank you for the information!

Neuro Central
The best of 2018 – an A–Z of neuroscience and neurology research

N

NICE
The National Institute for Health and Care Excellence (NICE) has made the headlines a few times this year with their recommendations against major drugs Ocrevus® (ocrelizumab) for MS and Spinraza® (nusinersen) for spinal muscular atrophy. In both instances, the cost–effectiveness of the drugs was deemed too high. Although Roche (Basel, Switzerland) offered a lower price for ocrelizumab, NICE were unable to accept a different price to that which they already pay for it to treat relapsing MS.

V

Vaccine
In the field of glioblastoma, we’ve seen an array of potential vaccine candidates emerge this year, such as a Zika glioblastoma vaccine and an immunotherapy (DCVax®-L) for newly diagnosed glioblastoma. Addition of DCVax-L to standard therapy was reported to be feasible and safe in patients, and may improve survival. More recently in the Alzheimer’s field, news of a DNA vaccine also reported decreased build-up of beta-amyloid and tau in the brains of mice.

https://www.neuro-central.com/2018/12/03/best-2018-z-neuroscience-neurology-research/#prettyPhoto